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AF:   amniotic fluid 
AFI:   amniotic fluid index 
AFV:   amniotic fluid volume 
AP:   amniopatch 
APTA:  antepartum transabdominal amnioinfusion 
BMI:   body mass index 
CI:   confidence interval 
CS:  cesarean section 
GA:   gestational age 
IUGR:  intrauterine growth retardation 
IVF-ET: in vitro fertilization and embryo transfer 
LGA:   large for gestational age 
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n.s.:   statistically not significant 
OR:   odds ratio 
PPROM:  preterm premature rupture of the membranes 
iPPROM:  iatrogenic preterm premature rupture of the membranes 
sPPROM:  spontaneous preterm premature rupture of the membranes 
RDS:  respiratory distress syndrome 
S.D.:   standard deviation 
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TAAC:  transabdominal amniocentesis 






Role of the amniotic fluid 
The amniotic fluid (AF) provides an ideal environment for fetal development and 
growth. It protects the fetus from trauma, and allows normal movements, which is important 
for musculoskeletal development. The AF provides the fetus with a source of water, 
participates in the fetal metabolism, maintains a constant temperature and plays a crucial role 
in the development of the fetal lungs
1,2
. 
The AF is predominantly composed of water
3
. It is of prime importance that the AF 
composition appears to be under much tighter control that of the AF volume (AFV). 
Abnormalities of composition are much rarer than those of volume, and in most cases of 
abnormality of volume the composition is normal for the gestational age (GA)
4
. During the 
first trimester, the composition of the AF is very similar to that of the extracellular fluid of the 
fetus; it is isotonic with the maternal or fetal plasma, but contains minimal protein
5
. It 
demonstrates an extremely low oxygen tension and high concentrations of sugar alcohols, 
because of the anaerobic metabolism
6
. With advancing gestation, its composition diverges 
from that of the plasma. Its osmolality and sodium concentration decrease, an effect thought 
to be a result of the production of dilute fetal urine. It has been well demonstrated that the 
fetal urine becomes increasingly hypotonic relative to the fetal plasma as gestation progresses, 
due to the relatively large glomerular filtration for the renal blood flow in the fetal 
metanephros
7
. Parallel to the decrease in osmolality, the urea, creatinine and uric acid 
contents of the AF increase during the second half of pregnancy
8
.  
Together with the changes in content, the AFV changes dramatically during 
pregnancy. The average AFV increases progressively from 1.5 ml at 7 weeks to 20-25 ml at 
10 weeks
9-11
, 630 ml at 22 weeks and 770 ml at 28 weeks of gestation
10
. At the beginning of 
pregnancy, the AFV is a multiple of the fetal volume, but they become equal after 20 weeks
3
. 
Between 29 and 37 weeks, there is only a slight change, with a peak around 34 weeks, and the 
AF subsequently decreases during the pregnancy
10,12
. At 30 weeks the AFV is about half and 





During the early weeks of pregnancy, the AF is a result of secretion from the amniotic 
or chorionic epithelium and the transfer of water across the fetal skin and umbilical vessels
11
. 
Fetal urine enters the amniotic space around week 8, and from the weeks 10-12 the fetal 
kidneys assume an increasing role in the regulatory process
3
. The AFV is the resultant of the 
inflow and the outflow in the amniotic space. The total AFV is exchanged within 3 h
2
.  As 
compared with the early stages of pregnancy, much more is known about the pathways 
involved in this regulation during the second half of gestation, after keratinization of the fetal 
skin.  
Production of the amniotic fluid during the second half of gestation 
1. Urine production 
It is obvious that the fetal urine is the predominant source of the AF, as evidenced by 
the almost complete absence of AF in the event of renal agenesis
13
. The amount of urine 
produced can be estimated through the ultrasonographic assessment of the fetal bladder 
volume
14-18
. The latest studies indicate that in normal pregnancies the fetal urine production at 
25 weeks is approximately 7.5 ml/h, and at 40 weeks it is 71.4-125.1 ml/h
16-18
. A correlation 
has been found between the fetal urinary product and the fetal weight
19
, and the urine 
production can therefore be predicted via the simple measurement of biometric parameters
19
. 
It has been demonstrated that the fetal urine contains an active substance which stimulates the 
intramembranous transport of the AF across the amnion into the underlying fetal 
vasculature
20
, and thus the fetal urine takes part not only in the production, but also in the 
ekimination of the AF. The urine production can be affected by several factors. In 
complicated pregnancies, the urine production can change appreciably
21-23
, which strongly 
affects the AFV.  
2. Fetal lung fluid production 
The rate of fluid production by the human fetal lungs has not been measured, and the 
available data are derived from the ovine fetus. During the last third of gestation, the fetal 
lamb secretes an average fluid volume of 100 ml/day/kg from the lungs. Half of this liquid 
mixes with the AF and half is swallowed. Around 18% of the swallowed fluid is derived from 
the fetal lungs
24
. Under physiological conditions, the total lung fluid production is about one-
third of the urine production and the AF contribution is only one-sixth of the urine
1
. The 
secretion rate has been shown to be influenced predominantly by hormones and neural 
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. It has been 
reported that the secretion rate is unaltered in the case of a rapidly reduced AFV
28
, but a 
chronic AFV decrease results in a reduced lung fluid secretion rate
29
. The fluid production 
seems to be fairly constant at a maximum rate, and the modulation of lung fluid production is 
therefore unlikely to be a significant modulator of the AFV. It is most important in serving for 
pulmonary expansion, which is necessary in normal airway and alveolar development
1
.  
3. Transmembranous pathway of fluid exchange 
On the basis of compartmental analysis, it was assumed that there is an exchange of 
water between mother and conceptus by ways outside the fetal-placental circulation
30
. This 
exchange involves diffusion and the filtration of water
31
 and it occurs across the fetal 
membranes between the AF and the maternal blood within the wall of the uterus
32
. The 
expression „transmembranous pathway” is used to describe this phenomenon. The 
contribution of this pathway changes with advancing gestation since the net volume transfer 
across the membranes is inward early in gestation and outward during late gestation. As 
compared with other factors in the AF regulation (e.g. fetal urine, lung secretion and fetal 
swallowing), there is little support for a significant contribution of transmembranous fluxes to 
the AFV and composition in the second half of gestation
32
. 
Elimination of the amniotic fluid during the second half of gestation 
The elimination of the AF involves two main regulatory mechanisms.  
1. Fetal swallowing 
Fetal swallowing has been demonstrated to be a secondary contributor in AFV 
regulation. The human fetus swallows an average of 210-760 ml/day
33
 and, within certain 
limits, this mechanism can afford protection from the development of either oligohydramnios 
or polyhydramnios
34
. Although fetal sheep with a ligated esophagus can maintain the normal 
AFV under experimental circumstanxes
35
, in cases of esophageal or intestinal atresia 
polyhydramnios usually develops in human pregnancies
36
. 
2. Intramembranous pathway of fluid exchange 
In the second half of pregnancy, „intramembranous” fluid exchange is important; this 
is large in magnitude and plays a major role in regulating both the AFV the and 
composition
37,38
. The regulatory function of this pathway even outweighs the role of fetal 
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swallowing. Intramembranous absorption allows the movement of the AF and solutes directly 
to the fetal blood. This occurs through a microscopic network of fetal blood vessels on the 
fetal surface of the placenta
39,40
. Based on a mathematical model, the basal intramembranous 
absorption in the late-gestation ovine fetus is 200-400 ml/day
32
, and a similar extent can be 
assumed in the human fetus
41
. Under experimental conditions, in the event of AFV loading, 
the intramembranous absorption increases dramatically as a compensatory mechanism
32,42
. 
Some of this absorption occurs passively, because the AF is hypo-osmotic with respect to the 
fetal plasma, but an active component of this fluid exchange has also been demonstrated
42-44
. 
Water can enter the fetal circulation from the AF through either paracellular or transcellular 
routes. In the regulation of the paracellular flux, changes in the amniotic tight junctions may 
have a central role
45




Assessment of the amniotic fluid volume in clinical practice 
 Oligohydramnios is believed to complicate 4-4.9% of pregnancies
47
. Oligohydramnios 
has six possible major causes: 1) a severe fetal abnormality, 2) preterm premature rupture of 
the membranes (PPROM), 3) an isolated/idiopathic form, 4) an impaired placental function 
leading to insufficiency, 5) a complication of multiple pregnancies, and 6) iatrogenic
48
. There 
are two peaks in the incidence of oligohydramnios, between weeks 13 and 21 and between 
weeks 34 and 42
49
. The AFV can be measured by dye dilution techniques at the time of 
amniocentesis
50
, or can be measured directly measured at cesarean section (CS)
51
. Dye-
determined AF measurements may give sufficiently accurate results, but there have been only 
a very limited number of investigations to date. This method is not appropriate for daily 
clinical routine, and the AFV is therefore estimated by ultrasonography. The AF index (AFI) 
varies with the GA
52
, and oligohydramnios is definied as a deficiency of AFV below the 5th 
percentile corresponding to the GA
53,54
. Besides the subjective estimation, two methods of 
assessment are frequently used in clinical practice: 1) the AFI
52
, and 2) measurement of the 
single deepest pocket (SDP)
55
.  
1. Amniotic fluid index 
During the measurement with this method, the amniotic cavity is virtually divided into 
four quadrants and the sum of the vertical diameters of these four areas gives the AFI. Several 






2. Single deepest pocket 
In the SDP method, the largest AF pocket is measured vertically. Chamberlain et al. 
evaluted the relationship of a SDP as an antenatal test in high-risk pregnancies, and found that 
the perinatal mortality increases with the severity of oligohydramnios
55
. During antepartum 
fetal surveillance, use of the SDP method resulted in a significantly lower rate of suspected as 
oligohydramnios compared with the AFI
60-62
. Both methods are currently frequently used in 
clinical practice. 
My investigation focused on the importance of oligohydramnios and the possibilities 
of its management. This thesis consists of three main parts: 
1. Assessment of oligohydramnios, other maternal and fetal risk factors and causes of 
death in pregnancies complicated with intrauterine fetal death. 
2. Meta-analysis of relevant publications on the treatment of oligohydramnios 
between 13-26 weeks of pregnancy. Expectant management, transabdominal 
amnioinfusion and amniopatch technique were compared especially in terms of 
survival, pulmonary hypoplasia and postural deformities. 
3. Observational study on the outcome of transabdominal amnioinfusion in case of 
idiopathic oligohydramnios between 16-34 weeks in our pregnant population. 
 
Analysis of oligohydramnios and other risk factors in cases with stillbirth 
through autopsy and placental examination reports 
Introduction 
In the third trimester, oligohydramnios has been reported to associated with increased 
level of labor induction, stillbirth, a nonreassuring fetal heart rate, iatrogenic premature 
delivery, meconium aspiration syndrome, admission to a neonatal intensive care unit and 
neonatal death
55,57-59,63-65
. On the other hand, the association between oligohydramnios and 
neonatal acidosis has not been sufficiently demonstrated; the observed adverse perinatal 
outcome results can be explained by the unnecessarily aggressive obstetrical management in 
the case of a reduced AF
59,62
. Other authors have found oligohydramnios to be a significant 





, while isolated oligohydramnios in the third trimester does not seem to 




There is no unequivocal conclusion regarding the effect of oligohydramnios on the 
pregnancy outcome in the third trimester. For our analysis, we chose the population of 
pregnancies complicated with intrauterine fetal death. Our aims were: 1) to identify the causes 
of stillbirth; 2) to analyze the association between this adverse outcome and pathologic 
obstetrical conditions such as oligohydramnios; and 3) to specify risk factors for intrauterine 
fetal death. 
Materials and methods 
We carried out a retrospective analysis on the total number of stillbirths that occurred 
at the Department of Obstetrics and Gynecology, University of Szeged, Hungary, between 
1996 and 2010. Only cases with a GA of 24 weeks or more were surveyed, and also stillbirths 
with a birth weight of at least 500 g if the GA was unknown. The GA was determined from 
the last menstrual period and confirmed or adjusted by ultrasonographic measurement of the 
fetal crown-rump length (8-10 weeks) or the biparietal diameter (12-20 weeks). The 
pregnancy characteristics and the comprehensive autopsy results were collected from the 
medical charts. The medical charts furnished the date of the delivery, the GA, the birth weight 
and the pregnancy details.  
The autopsies and placental histopathological examinations performed by the 
pathologists clearly demonstrated the cause of fetal death in most of the cases, but the clinical 
course was also considered. Subsequently, the cause of stillbirth was determined by a 
consensus between the gynecologists on the basis of relevant clinical findings that can explain 
subsequent stillbirth and the pathologists who reported the autopsy and placental 
histopathological results. 
IUGR was defined as a fetal weight below the 10th percentile, and a large for 
gestational age (LGA) fetus was defined as a fetal weight above the 90th percentile, using the 
Hungarian fetal growth and birth weight centiles
2
.  
Placental insufficiency was characterized by inadequate spiral artery remodeling 
and/or spiral artery pathology leading to a uteroplacental vascular insufficiency, such as (1) an 
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acute placental infarction (> 20%) and/or (2) calcification (> 20%), or (3) a placental 
hematoma with intervillous thrombosis. The placental insufficiency group included 
morphological abnormalities that arose because of abnormal developmental processes and 
acquired placenta parenchyma disorders that affected  > 20% of the villi/intervillous space (as 
classified at the Department of Pathology, University of Szeged). Placental lesions were also 
recorded by the pathologists when these histopathological observations did not reach a level 
of 20% and were not so severe as to cause stillbirth. An infectious cause of death was defined 
as autopsy evidence of organ involvement with an infectious organism and/or a histological 
placental examination with infectious findings
70
. 
The relationships between the fetal and the maternal characteristics were analyzed by 
means of the χ2 test. Statistical significance was defined at the two-sided p = 0.05 level.  
Results 
Overall 140 stillbirths and 29,897 births occurred during the 15-year period, 
representing an average stillbirth rate of 4.7 per 1000. One hundred and twenty-six of the 140 
stillbirths (90.0%) occurred in singular pregnancies, and the remaining 14 (10.0%) in twin 
pregnancies. The median GA at delivery was 31 weeks (range: 24-40 weeks), whereas two 
postdate stillbirths were recorded. The median maternal age was 28 years (range: 18-45 
years). Hypertensive disorders were present during pregnancy in 27 cases (19.3%), while 
diabetes occurred during pregnancy in 13 cases (9.2%). The incidences of the maternal risk 
factors are listed in Table 1. The most common fetal finding was IUGR, which was 
demonstrated in 67 of the 140 cases (47.8%). Oligohydramnios was diagnosed in 14 cases 
(10.0%) and the fetus was LGA in 12 cases (8.6%). A lethal abnormality was noted in 3.6% 
(5/140) of the cases. The incidences of the fetal risk factors are illustrated in Table 2. 
Both autopsy and placental histological results were available on 137 of the 140 cases 
(97.9%). The postmortem examination revealed the cause of death in 81 cases (57.9%), while 
56 cases (40.0%) remained unexplained (mean GA ± standard deviation (S.D.): 31.03 ± 4.29 
weeks). The results of the autopsy and the histological examinations of the placenta are 
presented in Table 3.  
As regards the explained cases (mean GA ± S.D.: 30.21 ± 3.50 weeks), the cause of death was 
placental insufficiency in 38 of the 81 cases (46.9%, mean GA ± S.D.: 30.21 ± 3.50  weeks), 
an umbilical cord complication (an umbilical cord knot, or a constricting loop around the 
13 
 
neck) in 21 cases (25.9%, mean GA ± S.D.: 32.81 ± 5.0 weeks), an infection in 8 cases (9.9%, 
mean GA ± S.D.: 29.37 ± 4.57 weeks), lethal congenital malformations in 5 cases (6.2%, 
mean GA ± S.D.: 32.4 ± 5.08 weeks), placental abruption in 5 cases (6.2%, mean GA ± S.D.: 
32.6 ± 4.45 weeks) and hydrops fetalis in 4 cases (4.9%, mean GA ± S.D.: 29.0 ± 3.56 
weeks).  










: Number of antenatal 
care visits ≤ ; c: Including all grades of pre-eclampsia, pregnancy-induced hypertension and 
essential hypertension; S.D.: standard deviation; IVF-ET: in vitro fertilization and embryo 
transfer 







IUGR: intrauterine growth retardation; LGA: large for gestational age 
Maternal age (year) (mean ± S.D.) 
28.5 ± 6.0 
Gestational age at stillbirth (week) 31.2 ± 4.0 





 31 22.1 
Inadequate antenatal care
b 29 20.7 
Hypertensive disorder
c
 27 19.3 
Advanced maternal age (>35 years) 22 15.7 
Maternal smoking 21 15.0 
Gestational diabetes mellitus 10 7.1 
Recurrent early pregnancy loss 7 5.0 
Pregnancy after IVF-ET 6 4.3 
Previous stillbirth 5 3.6 
Type1 diabetes mellitus 3 2.1 
Fetal risk factor N = 140 
n % 
IUGR fetus
 67 47.8 
Oligohydramnios 
 14 10.0 
LGA fetus 12 8.6 
Lethal congenital anomaly 5 3.6 
Isoimmunization 2 1.9 
Placenta previa 2 1.9 
Hydramnios 1 0.9 
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Placental lesions were recorded in 78 cases, but only 48.7% reached a level that could have 
led to stillbirth, whereas almost half of the unidentified cases (44.1%) exhibited pathological 
placental lesions. The categories of the causes of death by GA are illustrated in Figure 1. 
Unexplained deaths occurred predominantly up to 36 weeks of gestation. 
The prevalence of a placental insufficiency displayed a decreasing tendency 
throughout pregnancy. The proportion of stillbirths classified as involving umbilical cord 
pathology was highest in late pregnancy.  














24-28 weeks 29-32 weeks 33-36 weeks 37-40 weeks 
Placental insufficiency Umbilical cord pathology Other Unexplained 
Cause of death N = 140 
n % 
Placental insufficiency
 38 27.1 
Umbilical cord origin
 21 15.0 
Fetal infection 8 5.7 
Lethal congenital anomaly 5 3.6 
Placental abruption 5 3.6 
Hydrops fetalis 4 2.9 
Unexplained 56 40.0 
Either autopsy or histological examination 




A fetal infection was typically present at a lower GA, whereas lethal congenital 
abnormalities and placental abruption tended to complicate the pregnancies at a later stage. 
Discussion 
 To date, this is the first study published on the causes and risk factors of fetal death in 
Eastern-Central Europe. Fetal death is a sensitive obstetric care indicator and stillbirth still 
plays a major role in perinatal mortality
71
. The stillbirth rate worldwide varies from 2.1 per 
1000 to 40 per 1000 births
71,72
, and our rate of 4.7 per 1000 is in concordance with the data 
obtained from other high-income regions of the world
72
. 
 Despite our high autopsy/placental examination rate (97.9%), the number of 
unexplained stillbirths was still 42.1% of the total. In other studies, the rate of stillbirths with 
no apparent cause varied between 23.2 and 66.2%
70,73,74
, but the rate of unexplained stillbirths 




The most frequent maternal risk factors were maternal obesity, lack of adequate 
antenatal care and hypertensive disorders. From previous studies, it is clear that a relationship 
exists between maternal obesity and adverse pregnancy outcomes
76-78
. Maternal overweight 
(BMI = 25-30 kg/m
2
) and obesity (BMI > 30 kg/m
2
) pose an increased risk of fetal death
76,78
. 
Adult obesity rates in Hungary are amongst the highest in the OECD (Organization for 
Economic Co-operation and Development) area: about 27.6% of Hungarian women are 
obese
79
. Lack of antenatal care  is an important risk factor of an adverse pregnancy outcome 
such as preterm birth, low birth weight and perinatal death
80-82
. In our dataset, every fifth 
women (20.7%) had no adequate prenatal care during her pregnancy. An earlier study from 
our department revealed that the occurrence of uncared pregnancies in the population was 
1.0%
80
. Comparing these results, the contribution of the antenatal care system in stillbirth 
prevention is more emphasized. Several studies have confirmed that there is an increased risk 
of stillbirth in the event of hypertensive disorder in pregnancy
83-86
, independently of the type 
of hypertension. A meta-analysis of studies on pre-existing hypertension demonstrated a rise 
in the odds of stillbirth of around 2.6 times
76,85
. Pregnancy-induced hypertension was 
associated with a 30% increase, while pre-eclampsia was associated with a 60% rise in the 
odds for stillbirth compared to normotensive pregnancies
76,83,84,86
 . These results are consistent 
with our data. In our stillbirth dataset, the occurrence of all types of hypertensive disorders 
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was 19.3%, and the majority were pregnancy-induced hypertension or pre-eclampsia, since 
they occurred in 15.7% of the cases.  
 Growth disorders are the most important fetal risk factors in stillbirth. In our study, 
almost half of the cases (47.8%) involvedIUGR, while 8.6% were LGA. IUGR is associated 
with a 4-times higher risk of stillbirth
76
, and its proportion in our study is in concordance with 
other results which report the occurrence of 37.5-46.8% growth restriction in stillbirth
87-90
. 
Although it is possible to screen pregnancies for IUGR with ultrasonography, current 
antenatal detection rates of IUGR are reported to be only 25-36%
91-93
. Thus, more effective 
screening of fetal growth disorders could well play a pivotal role in the prevention of fetal 
deaths. In our study, however, in pregnancies with IUGR, the average GA was 30.6 ± 3.4 
weeks, and one-third of the stillbirth cases involving IUGR occurred before 28 weeks. It 
should be noted that it is highly debatable that stillbirth may be prevented through labor 
induction or even operative delivery in this critically early period of the third trimester.  
In our sample, the most frequent cause of stillbirth was a placental insufficiency,  
which occurred in 46.9% of the explained cases, in accordance with the 49.9% reported by 
Korteweg et al.
75
. The high frequency of pathological conditions of the placenta in fetal death 
cases may suggest causality between the placental pathology and fetal demise
74,75,87
. Placental 
disease could be the primary cause of abnormal fetal development and poor fetal growth. 
These histopathological findings could be present in a placenta in an uncomplicated 
pregnancy, but their grades are enhanced in pregnancies complicated with stillbirth
94
. 
Oligohydramnios occurred in 10% of the cases and appeared to be a noteworthy factor 
in fetal death. This prevalence is at least double that reported in population studies
47,95
. It is of 
paramount importance that oligohydramnios was significantly associated with IUGR: 78.6% 
of the fetuses with oligohydramnios were growth-retarded. No other condition was found to 
be associated with a low AFV. In the group of stillbirths, we found a significant difference 
between the fetal weight with oligohydramnios and without (871 ± 648 g vs. 1619 ± 910 g; p 
= 0.006), but there was not a significant difference regarding the placental weight with and 
without low AFV (248 ± 126 g vs. 336 ± 161 g; p = 0.24). Our result seems to support the 
observation of Apel-Sarid et al.
66
, who found oligohydramnios to be a significant risk factor 
for an adverse perinatal outcome in pregnancies complicated with IUGR. Nevertheless, they 
were not able to present any differences in placental pathologies by comparing cases with or 
without oligohydramnios. The role of a reduced AFV in the prediction of fetal death is still 
17 
 
questionable. The fundamental work of Chamberlain et al. demonstrated a more than 55-fold 
increase in perinatal mortality if serious oligohydramnios was present
55
. Several studies found 
oligohydramnios to be an independent risk factor of intrauterine fetal death
56,65,96
 . Chhabra et 
al.
97
 reported a perinatal mortality of 18% in a group of high-risk pregnancies with 
oligohydramnios. However, the suggestion has emerged that the observed adverse perinatal 
results may be explained by the unnecessarily aggressive obstetrical management
59,62,63,98
.  
The confusing data on the predictive value of oligohydramnios for adverse outcomes can be 
explained by the difference in pregnancies with a reduced AFV. Zhang et al.
69
 demonstrated 
that oligohydramnios with unfavorable maternal and/or fetal conditions, such as IUGR, fetal 
anomalies or hypertensive disorders, leads to a much worse perinatal outcome than a normal 
AFV with the same conditions (perinatal mortality 5.1% vs. 1.2%). However, they found that 
about half of the oligohydramnios cases did not have any coexisting medical or obstetric 
conditions. Fetuses in these cases tend to be appropriately sized at the diagnosis of isolated 
oligohydramnios and their perinatal outcomes are similar to those of pregnancies with a 
normal AFV
69
. The occurrence of such isolated oligohydramnios is more frequent at 
term
49,68,99




Treatment strategies for severe second and early third trimester 
oligohydramnios 
Introduction 
Several stages of fetal lung development can be distinguished on the basis of the 
histological lung morphology: the embryonal, pseudoglandular, canalicular, saccular and 
alveolar phases. As the transitions between these stages are fluent, the schedule of lung 
growth is quite arbitrary. The tree of conducting airways has fully developed by a GA of 16 
weeks
100
. The subsequent canalicular phase is characterized by a widening of the airway 
lumina, the growth of respiratory airways, and a flattening of the gas-exchanging epithelium, 
which is accompanied by a growth spurt of the distal pulmonary vasculature. Massive 
angiogenesis leads to a dense capillary network surrounding the forming alveole
101
. During 
the canalicular phase, two kinds of mechanical forces affect the developing lungs: one is the 
transpulmonary pressure, built up by the permanent secretion of lung fluid, and the other is 
cyclic stretch, generated by fetal breathing movements
102
. Between 24 and 26 weeks, the 
structural maturation of the lung tissue reaches the saccular stage, a state that allows 
extremely preterm infants to survive with the aid of intensive neonatal care. Still, the 
biochemical lung maturation has just begun: differentiated type 2 alveocytes are beginning to 
produce surfactant
102
. Alveolar structures can be recognized histologically by a GA of 32 
weeks, and are uniformly present at 36 weeks
103
. However, 85% of the alveoli are formed 
after birth, with intense multiplication during the first 2 years of life
104
. 
There is a huge difference between the consequences of oligohydramnios before and 
after the onset of pulmonary maturation. Extreme and persistent mid-trimester 
oligohydramnios, prior to 22-24 weeks, before the saccular stage of lung development, leads 
to pulmonary hypoplasia. This poses a risk of perinatal mortality as high as 80%
105
, and 
survivors often have to face chronic pulmonary morbidities. Additionally, there is an 
increased risk of cord compression, joint contractures, skeletal anomalies, growth delay and 
pregnancy loss
106
. The proper management of these cases is still a great challenge for both the 
obstetrician and the pediatrician. Evidence is currently accumulating that suggests the better 





 Our aim was to determine the efficacy of frequently used processes (antepartum 
transabdominal amnioinfusion (APTA), amniopatch (AP) and conservative management) in 
the treatment of early onset (13-26 weeks) oligohydramnios. We compared the outcomes of 
the conservative approach with the results of invasive strategies.   
 Materials and methods 
 A systematic review and meta-analysis were conducted. Studies on the management of 
second  and early third trimester (13-26 weeks of gestation) oligohydramnios were reviewed 
from 2000 to 2013 in the conservative management and the APTA group, and all the reported 
cases with AP were analyzed. In the pooled analysis, the χ2 test and Student’s t-test were 
applied. Statistical significance was defined at the two-sided p = 0.05 level.  
 Results 
 Nine studies in the APTA group, 12 studies in the AP group and 7 studies in the 
conservative management group were analyzed.  
The expectant management delayed pregnancy by a mean latency of 11.8 days (range 
0-163). Pulmonary hypoplasia developed in 31.8% in this group. The overall perinatal 
survival rate following expectant management was 29.3%, while deformation defects 
occurred in 53%. The sum of the analyzed studies with conservative treatment is shown in 
Table 4. In the APTA group, the latency was significantly longer, at 37.4 days (p < 0.001). 
Pulmonary hypoplasia developed in 23.3%, although chronic lung diseases complicated the 
neonatal period in 34.8%. The overall perinatal survival was 49.1%, and the deformation 
defects were reduced to 36.5% (p < 0.05) by APTA. Severe maternal complications such as 
infection or placental abruption occurred in 22.4%. After AP, the pregnancy was delayed by 
44 days (p < 0.001). The rates of both pulmonary hypoplasia and chronic lung diseases were 
below 1%. The perinatal survival was 61.4%. Postural deformity was not recorded among the 
AP survivors. The rate of procedure-related maternal complications was 28.2%, but serious 
complications such as infection or placental abruption occurred in only 8.3%. Tables 5 and 6 




Table 4. Conservative management of severe oligohydramnios in the second and early third trimester (13-26 weeks) 
 
RDS: respiratory distress syndrome; sPPROM: spontaneous preterm premature rupture of membranes; iPPROM: iatrogenic preterm premature rupture of 









































































































































































































































































65/ 18/ 17 not 
given 
25 17 42 not 
given 
25 33.3 












11.1 60 not given 11.1 7.4 n.g. 9.5 
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Locatelli et al. 
(2000)
114 
sPPROM n = 32 
iPPROM n = 4 




0/27/73 10 not given not given not given 18 not given 0 








sPPROM n = 11 single = 4 







10 not given not given 27.3 (of 
liveborns) 
27.3 not given not given 
Tan et al. 
(2003)
116 
sPPROM n = 6   single = 4 







33.3 33.3 16.7 not given not 
given 
not given 0 
De Santis et 
al. (2003)
117 
sPPROM n = 29 
iPPROM n = 8 
single = 5 
serial = 32 
(mean ± SD) 
20.1±2.8 
 




20.8 22.2 not given 16.6 16.6 not given 20 
Stefos et al. 
(2005)
118 
iPPROM n = 2 serial = 2 16.3 and 16.4 140 0/0/100 0 0 0 0 0 0 0 




iPPROM n = 1 
sPPROM n = 2 
Idiopathic  
n = 8  
single = 8 








16.7 not given not given not given not 
given 





n = 17 
single = 11 








0 14.2 42.8 14.2 (of 
liveborns) 
14.2 0 0 
Agressive treatment 
Chen et al. 
(2005)
121 
sPPROM n = 4 
Idiopathic n = 7 











not given not given not 
given 










13.2 83.3 34.2 (of 
liveborns) 
7.9 0 34.3 33.3 
RDS: respiratory distress syndrome ; sPPROM: spontaneous preterm premature rupture of membranes; iPPROM: iatrogenic preterm premature rupture of 
membranes; SD: standard deviation 
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Sener et al. (1997)
123 
iPPROM n = 1 (after 
TAAC) 
16.1 147 0/0/100 0 0 0 0 0 0 0 
Quintero et al. 
(2003)
124 
iPPROM n = 26 
(39 fetuses) 
(9 after TAAC, 1 after TA-












not given 2.6 0 0 0 
Young et al. 
(2004)
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Contino et al. 
(2004)
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iPPROM n = 3 










Lewi et al. (2004)
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Cobo et al. (2007)
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Mandelbrot et al. 
(2009)
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Ferianec et al. 
(2011)
132 
sPPROM n = 1 19.1 84 0/0/100 0 0 not given not given not 
given 
not given 0 
Kwak et al. 
(2013)
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Richter et al. 
(2013)
134 
iPPROM n = 13 









16.7 25 not given not given not 
given 
not given 25 
iPPROM n = 11 








0 0 not given not given not 
given 
not given 7.7 
RDS: respiratory distress snydrome; sPPROM: spontaneous preterm premature rupture of membranes; iPPROM: iatrogenic preterm premature rupture of 




Figure 2. Outcomes of three management strategies in cases of second and early third 
trimester (13-26 weeks) oligohydramnios 
 
⃰ : p < 0.001 and  ⃰  ⃰ : p < 0.05 compared to conservative management 
Discussion 
In our study, we aimed to analyze the latest perinatal results in midtrimester 
oligohydramnios management, since the improvement of neonatal intensive care units has an 
outstanding impact on the perinatal outcome. Due to the advances in obstetrical and neonatal care, a 
marked increase in neonatal survival has occurred during recent decades. The survival of very low 
birthweight (501-1000 g) infants improved from below 10% in 1959 to over 60% in 2009
135
. 
However, the prognosis of midtrimester oligohydramnios is still poor. Besides the fetal 
malformations, PPROM is the most frequent cause of a decreased AFV in this period of gestation. 
The traditional obstetric management includes the administration of tocolytics and antibiotics to 
prolong latency and steroid administration to enhance pulmonary maturity
136
. Miyazaki et al.
122
 
demonstrated amniotic sac inflammation via histopathology in 91% of women with PPROM and in 
more than one-third of the cases clinical signs of chorioamnionitis appear
137
. Broad-spectrum 
antibiotic treatment results in a lower frequency of chorioamnionitis and improved fetal survival as 
compared with patients without antibiotic administration
138
















Survival (%) Maternal 
complications 
(%) 
⃰ ⃰  ⃰  
⃰  ⃰ 
⃰ 
⃰ ⃰ 
⃰  ⃰ 








antibiotics has increased up to 97% in cases with PPROM
139
. However, it is noteworthy that intra-
amniotic inflammation can merely be controled, and not eradicated with antibiotic therapy: 
subclinical chorioamnionitis remains despite the treatment
122
. The use of tocolysis is controversial, 
though a moderate effect on the latency period is suspected
138,140
. Antenatal corticosteroid 
administration seems to improve the neonatal survival rate significantly
138
 and it is recommended 
when viability has been reached. In the conservative treatment group, we demonstrated a mean 
latency of only 11.8 days from rupture of the membranes until delivery. 73% of the pregnancies 
ended within 2 weeks after rupture of the membranes. In the majority of the cases, the fetus could 
not reach the limit of viability during this short period, so conservative management resulted in less 
than a 30% survival rate. As regards pulmonary hypoplasia, the gold standard for diagnosis below 
28 weeks of gestation is the post-mortem findings of a  pulmonary weight to body weight ratio of < 
0.015 (1.5%)
141
, though age-matched reference values can identify discrete, but potentially critical 
degrees of pulmonary underdevelopment more sensitively
142
. In our analysis, pulmonary hypoplasia 
was present in at least 31.8% of the liveborns, and the most important prognostic factors were the 
residual AFV and the GA before delivery
137,151
. If oligohydramnios does not develop, the neonatal 
survival rate reaches 92% despite PPROM
114
. 
APTA is the method that has been addressed as a technique for the restoration of a normal 
AFV, in order to prolong gestation and to prevent fetal complications at least until pulmonary 
maturity is achieved
120,122,143
. The technical equipment is similar to that used for amniocentesis; it is 
performed with
144
 or without local anesthesia
120
, usually with a 20-22-gauge 150-mm amniocentesis 
needle, which is introduced
116,120,144
 transabdominally into the widest amnion pocket with the 
assistance of real-time ultrasonographic guidance
114,145
. The infused crystalloids are 0.9% saline 
solution or Ringer’s lactate solution at body temperature, which are both isotonic and do not induce 
any electrolyte imbalance in the fetus
146
. The infused volume should depend on the GA and the 
amount of AF remaining inside the amniotic cavity
144,147
. Our analysis demonstrated that the 
survival increases to 49.1%, which is a significant improvement as compared to expectant 
management. This encouraging result can be derived from the significant increase in latency time 
and a slight reduction in the rate of pulmonary hypoplasia due to the restored AFV. The survival 
rate for infants born alive increases progressively from 26% at 23 weeks to 84% at 26 weeks
148
, and 
prolongation of the pregnancy is therefore of paramount importance. Some authors waited several 
days from the onset of AF leakage until the first APTA
114,117,119
. The rate of spontaneous resealing 
is only 6-11%
149,150
, while the risk of infection is high, and there is therefore no support for this 4-7 
day delay until the first procedure. The extent of fluid loss after APTA has an impact on the success 
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of the treatment. De Santis et al. demonstrated that fluid loss occurred within 6 h after APTA in 
100% of the neonates with pulmonary hypoplasia, as compared to 31.6% of the cases without
117
. If 
persistent oligohydramnios (deepest pocket of fluid 2 cm or less) requires serial APTA, lower 
neonatal survival and higher rates of pulmonary hypoplasia can be expected
114,151,152
. In this group, 
oligohydramnios recurs within 1-48 h after treatment
151
. In view of this phenomenon, some authors 
suggest a test APTA to select appropriate cases of second and early third trimester PPROM for 
repeated APTA
116
. If the initial fluid is retained, the patient may benefit from serial treatment. In 
contrast with patients with ruptured membranes, serial APTA seems to be beneficial over a single 
procedure in cases of oligohydramnios with intact membranes. In our study population, serial 
procedures provided a longer latency period (repeated APTA: 69 days vs. single APTA: 10 days; p 
= 0.002) and delivery at a higher GA
120
. Although membrane rupture occurring before and at the 
limits of viability complicates less than 1% of all pregnancies
153
, infants who die as a result of 
preterm birth are born overwhelmingly at previable or periviable GAs
154
. As a consequence, an 
„aggressive” management of PPROM was introduced121,122. Within the framework of the treatment, 
patients are given hospital bed rest, and the administration of antibiotics and tocolytic drugs. 
Emergency cerclage is performed and serial APTA is applied through an indwelling catether until 
delivery. The maternal and fetal status are closely monitored for the development of 
chorioamnionitis, labor and/or fetal compromise
122
. With this aggressive approach, a survival rate 
of 60-80% can be attained
121,122
, but the proportion of chronic lung diseases and late neurological 
complications are relatively high (83.3% and 33.3%) among survivors
122
. 
 The use of invasive prenatal diagnosis and fetal surgery has increased during recent years. 
iPPROM remains one of the most common complications. The risk of fluid leakage after a simple 
needle procedure is around 1.7%
155
, with sustained oligohydramnios reported in 0.3%
156
. 
Biochemical leakage is much more frequent, but usually without any clinical consequences
157
. Most 
pregnancies with iPPROM after amniocentesis will show the cessation of leakage and restoration of 
the normal AFV
111
. After a fetoscopic procedure, iPPROM occurs in 5-30%, depending on factors 
such as trocar size and surgical duration
158
. The use of AP is an accepted novel technique to achieve 
artificial membrane sealing following iatrogenic AF leakage. The method was first introduced after 
spinal anesthesia as an epidural blood patch
159
, and it was first used to control postamniocentesis 
amniorrhea in 1997 by Sener et al.
123
. During the procedure, warm isotonic saline (50-200 ml, 
optionally mixed with antibiotics) is infused intra-amniotically under ultrasonographic monitoring 
without knowledge of the exact site of rupture of the amniotic membranes. Cross-matched allogenic 
platelets [20-40 ml (0.5 units)] are infused, followed by 0.5 units of cryoprecipitate (including 
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clotting factors). Another 100 ml of normal saline is then instilled to achieve the optimal (> 5 cm) 
deepest pocket of the AF bag. Theoretically, the platelet/cryoprecipitate plug may seal the amniotic 
membranous defect by artificial platelet activation and fibrin adhesion at the site of the rupture, 
forming a ‘white’ coagulum as a plug123,124,126,133. In our analysis, the overall perinatal survival rate 
was highest (61.4%) after treatment with AP. Although the amniotic leakage relapsed in 50.7%, the 
GA achieved at delivery (median 29.4 weeks) was significant. This technique is basically 
performed in the case of iPPROM. In sPPROM cases, the AP predominantly fails, usually because 
of infection
133
. The membrane defects after needle-based procedures or fetoscopy are usually well 
demarcated and relatively small, and the needles or trocars are usually inserted into the uterine 
cavity under sterile circumstances. The membrane defects after sPPROM are mostly large, poorly 




 About  37% of patients with conservative treatment of midtrimester rupture of the 
membranes will have clinical signs of chorioamnionitis. Our analysis revealed that, compared with 
this, both the APTA and the AP technique had a lower complication rate. Severe maternal adverse 
events (infection or placental abruption) occurred in 22.4% of the APTA cases, and in only 8.3% in 
the AP group. 
To date, 26 cases have been reported with AP treatment in cases of sPPROM. The procedure 
was successful in only 3 cases (11.5%)
124-126,132,133
. This low success rate limits the use of AP for 




Despite the encouraging results of the active management of PPROM in the second and 
early third trimester, the patients are still in need of accurate information regarding the neonatal 
outcome and the risk of the intervention. Our analysis demonstrated that 25.8% of the patients opted 




Management of severe idiopathic oligohydramnios with antepartum 
transabdominal amnioinfusion 
Introduction 
 We have demonstrated that the second major factor contributing to fetal death was the 
presence of oligohydramnios
162
, but the exact role of oligohydramnios in third trimester fetal loss is 
still unclear
55,57-59,62-65,68,69
. APTA has been proven to be an acceptable treatment option for the 
prevention of fetal complications in both the second and third trimesters 
97,163
. The AFV is 
artificially increased by the injection of normal saline or Ringer lactate solution transabdominally or 
transcervically into the amniotic cavity. The infusion of 250 ml of fluid is believed to increase the 
AFI by 4 cm
147,164
. Augmenting the AFV may decrease the associated risk of oligohydramnios and 
increase the perinatal survival
97,144,163




 The objectives of the present observational study were to evaluate the outcome of 
pregnancies complicated by severe idiopathic oligohydramnios that were managed by APTA in the 
second or third trimester, and to identify the possible pregnancy complications related to the 
procedure. The maternal complications were also determined. 
 Materials and methods 
 We performed our study on patients presenting at the fetomaternal unit of the Department of 
Obstetrics and Gynecology, University of Szeged, Hungary, with severe idiopathic 
oligohydramnios (AFI < 5 cm) during the period between December 2009 and January 2012. All 
possible cases with severe idiopathic oligohydramnios were enroled into the study. The patients 
were in either the second or the third trimester, and the aim was prolongation of the gestation. 
Inclusion criteria were as follows: a) < 34 weeks of gestation; b) a singleton pregnancy; c) no 
PPROM; d) no symptoms indicative of incomplete abortion before 24 weeks of gestation; e) no 
active labor (< 3 cm of cervical dilatation; < 2 uterine contractions every 10 min) after 24 weeks of 
gestation; f) no clear signs of maternal or fetal infection (maternal tachycardia > 100/min, maternal 
temperature > 38°C, maternal white blood cell count > 15,000/ml, maternal C-reactive protein > 20 
mg/l, uterine tenderness, a foul-smelling vaginal discharge, fetal tachycardia > 160 bpm); and g) no 
suspicion of placental abruption (uterine tenderness and “unexplained” bleeding episodes). We 
29 
 
excluded from the study women with pregnancies complicated by lethal congenital abnormalities 
and women who declined after giving their informed consent. At presentation, all the women were 
examined to exclude rupture of the membranes (vaginal AF loss)
166
. The GA was confirmed on the 
basis of a first-trimester ultrasonographic examination. The AF was assessed by using the AFI with 
the sum of the four quadrants maximum pockets of AF
52
. Severe oligohydramnios was diagnosed 
when the AFI was < 5 cm irrespective of the pregnancy duration, and APTA was performed without 
delay. All APTA procedures were performed by the same experienced sonographer. Under sterile 
circumstances, without sedation, a Chiba 20® 150-mm needle (Neomed Corporations, Debrecen, 
Hungary) was introduced transabdominally into the amniotic cavity, into the widest pocket of the 
amnion, under ultrasonographic guidance (Kretz Sonoace 8000, Voluson 730Pro). A variable 
volume of 37 °C saline solution (0.9% NaCl, 180-900 ml) was infused transabdominally into the 
amniotic cavity under continuous ultrasonographic control. The infusion of 250 ml of fluid is 
believed to increase the AFI by 4 cm
147,164
, but saline solution was infused until a normal amount of 
fluid was restored exceeding the upper limit of moderate oligohydramnios (AFI = 5-8 cm)
47
. After 
this, an ultrasonographic fetal morphological evaluation was carried out by the same examiner. The 
fetal biometric parameters, the heart rate before and after the procedure, the location of the placenta 
(anterior, posterior or lateral), and the amount and the duration of the APTA were recorded. 
Prophylactic antibiotic therapy was not administered in any of the cases. The vaginal leakage of 
fluid was monitored continuously by the patient herself. The patients were followed up weekly for 
repeated AFI measurement in order to assess the need for further infusions (AFI < 5 cm). In the 
event of a lethal malformation of the fetus, termination of the pregnancy was offered to the patient. 
After the filling of the amniotic cavity, lethal abnormalities (bilateral renal agenesis) were noticed 
in 4 cases, which were excluded from the statistical analysis. Karyotyping from the sample during 
this procedure revealed only negative results in all of the included cases. A repeat ultrasonographic 
examination was carried out within 24 h after the procedure in order to control recurrence or 
PPROM. In cases of ongoing pregnancy, ultrasonography was performed weekly to assess the need 
for further infusion (AFI decreased below 5 cm again). Statistical analysis was performed with the 
SPSS for Windows program (SPSS 15.0, Inc. Chicago, IL, USA). Comparisons were assessed by 
the Kruskal-Wallis test for continuous variables. χ2 analysis with the Yates correction when 
necessary, or the Fisher exact test was used to test differences in proportions. A confidence level of 
p < 0.05 was taken to indicate statistical significance. Formal confirmation that ethical approval was 





 Altogether 20 cases fulfilled the criteria for enrollment. The mean GA at the time of the 
initial APTA was 22.6 weeks (range: 16.0-33.9 weeks). The mean number of infusions was 1.5 per 
pregnancy. APTA due to recurrent oligohydramnios was performed once in 14 pregnancies, twice 
in 3 pregnancies, 3 times in 2 pregnancies and 4 times in 1 pregnancy. Thus, a total of 30 APTAs 
were performed. The procedures were mostly repeated weekly in serial cases. The duration of 
pregnancy at the time APTA was performed was < 24 weeks in 70% of the patients; and < 33 weeks 
in 25%. Ten amnioinfusions were complicated by spontaneous abortion (50.0%) (started by vaginal 
AF loss, followed by uterine activity within 3 days from the procedure) and one intervention was 
followed by intrauterine fetal demise (5.0%; 1/20). Most of the single procedures (71.4%, mean 
GA: 19.4 weeks) were carried out in the second trimester, but all single APTA processes at that 
stage resulted in spontaneous abortion after a short latency period (mean: 4 days; range: 0-14 days). 
The vast majority of repeated procedures were also started in the second trimester (83.3%), with the 
exception of the case where the oligohydramnios was detected at 33 weeks of gestation, and 3 series 
of APTA were given. The interval between the first infusion and the spontaneous abortion/delivery 
(latency period) was 27.6 ± 37.2 days.  Serial procedures led to delivery at a higher gestational age 
than the single procedures (latency period: p = 0.002; repeated: 69 days vs single: 10 days). For 
patients with a GA between 16 and 24 weeks, the latency period ranged from 1 to 121 days. The 
mean latency period for this interval was 30 days. For the women with a pregnancy duration 
between 25 and 28 weeks, the mean latency period was 7 days; for those with a GA of >28 weeks, 
the mean latency period was 29 days. A schematic overview of the study cases is presented in 
Figure 3. The clinical characteristics of the pregnancies of the women undergoing spontaneous 
abortion and delivery are displayed in Table 7. (One case was excluded where a procedure was 
performed twice from weeks 23 of gestation, but the pregnancy resulted in intrauterine fetal demise 




In 7 of the pregnancies below 24 weeks of gestation, PPROM developed after APTA and 
spontaneous abortion occurred within 3 days after the procedure. In 4 of these 7 cases, 
retroamniotic filling of saline solution and a floating amniotic membrane were observed 
immediately after the start of the procedure following introduction of the needle into the insertion 
site (Figure 4). Retroamniotic filling with approximately 20-30 ml of administered saline went on to 
develop rupture of the membranes (vaginal AF loss) within 48 h of the APTA in every case. One 
woman with a 19-week pregnancy developed chorioamnionitis within 24 h after APTA despite the 
fact that there were no clinical signs of spontaneous abortion preprocedure, such as maternal fever, 
uterine activity or bleeding. Microbiological examination revealed Mycoplasma infection. 
However, in terms of perioperative complications of the deliveries, there was only one case of 
PPROM within 24 h of the APTA, but this pregnancy continued until premature delivery at 28.3 
weeks of gestation. (In another case, we started to inject the saline infusion into the fetal abdominal 
cavity by accident; the needle was removed to the amniotic cavity immediately and the procedure 
was continued with no fetal complication. The fetal intra-abdominal fluid was absorbed within 24 h, 




Table 7. Pregnancy characteristics in severe oligohydramnios cases trated with 
transabdominal amnioinfusion  
Statistical comparisons were performed with the Mann-Whitney U test test and the Fisher exact test for 
continuous and categorical variables, respectively; S.D.: standard deviation; n.s.: statistically not 
significant; OR: odds ratio; 95% CI: 95% confidence interval; 
Women who delivered after APTA were at a more advanced age than those whose 
pregnancies were followed by spontaneous abortion, but without any significant difference. The 
rates of primigravidity and previous CS did not differ statistically significantly between the two 
groups. The two groups were also similar in terms of the number of previous deliveries. 
Interestingly, no case of oligohydramnios had been recorded in the previous pregnancies. The rates 
of congenital abnormalities in the previous pregnancies were very low in both groups. There was no 
report of any hypertension prior to or during pregnancy in any of the cases. No other maternal 
complication was present in any of the pregnancies. In 4 cases, delivery occurred at term, whereas 
more than half of the deliveries (5 cases) took place prematurely. 
 Pregnancy followed 
by delivery (n = 9) 
 Procedure-related 
spontaneous 
abortion (n = 10) 
  
 n %  n %  p value OR (95% CI) 
Maternal age (years) 
(mean±S.D.) 
32.7 ± 4.6  30.1 ± 8.0 
 
n.s.  






































Gestational age at 
spontaneous abortion / 
delivery  








Premature birth 5 55.6  - -    









Retroamniotic filling - -  4 40    
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Four (44.4%) had a normal vaginal delivery, while 5 (55.6%) underwent a CS. Perinatal 
complications in liveborn cases are listed in Table 8. The APTA procedures were successful and 
uneventful in 78.6% of the pregnant women in terms of fetal complications; however, temporary 
fetal bradycardia was observed in 3 cases during the procedure. No maternal intraprocedural 
complications were recorded. One neonatal death occurred, in a case when APTA was followed by 
PPROM after a 5-week period, and delivery at 28.3 weeks of gestation. Perinatal death occurred on 
the fourth postpartum day, due to Pseudomonas infection. None of the neonates presented external 
lesions due to the APTA procedures. Table 9 compares the APTA-related characteristics in the two 
groups. The GA at the initial APTA was similar in the two groups, but the latency period was 
longer in the pregnancies that were followed by deliveries. The women who underwent spontaneous 
abortion received a single APTA, whereas those who delivered received serial APTA more 
commonly, but with no significant difference. The overall mean amount of fluid infused was 397.3 




Table 8. Times of intervention and delivery, and perinatal complications in liveborn cases 
treated with transabdominal amnioinfusion due to severe oligohydramnios 
 GA: gestational age; CS: Cesarean section; RDS: respiratory distress syndrome; NEC: necrotizing 
enterocolitis 
The amount of fluid infused at the first procedure was not significantly different in the two groups, 
whereas the overall mean volume was statistically significantly higher amongst those who 
delivered. Paradoxically, a higher amount of infused fluid posed a lower risk factor as concerns 
rupture of the amniotic membranes, but not significantly so.  Pregnancies with PPROM [n = 7]: 340 
± 101 ml vs. pregnancies not complicated by PPROM [n = 9]: 433.1 ± 110 ml; p < 0.05. Serial 
APTA led to PPROM in only 1 case [not presented in the Table]. It is of note that there were no 
cases of fetal distress, and tocolytics were not administered to any patient as most of the preterm 
pregnancies presented with advanced labor (uterine contractions), and 1 case had chorioamnionitis 
for which immediate delivery was indicated. It is also important that there were no recorded cases 
of pulmonary hypoplasia.  
Discussion 
In our previous review, we demonstrated the benefit of APTA treatment in the event of PPROM in 
the second trimester
163
. In contrast, there is currently a lack of evidence supporting this procedure 
amongst idiopathic cases of severe idiopathic oligohydramnios
144
. Accordingly, our present 
investigation focused on selected cases with no obvious reason for severe oligohydramnios. As 
concerns the results, the prevalence of fetal loss (55%) was unexpectedly high. 
 










1 21.9 26.1 39.3 3230 g, female 9/10/10 - 
2 33.3 37.3 2390 g, female 9/10/10 - 
3 21.0 21.7 22.3 29.0 1350 g, male 4/4/7 
preterm labor, RDS, foot 
deformity 
4 33.9 34.7 35.7 38.0 2680 g, male 10/10/10 breech presentation, CS 
5 21.6 23.4 38.9 3120 g, male 10/10/10 
agenesis of left kidney, 
hypoplasia of right kidney 
6 22.9 24.9 26.3 28.9 29.9 990 g, male 7/8/8 placental abruption, CS, 
7 24.3 28.9 1200 g, female 3/6/6 
preterm labor, breech 
presentation, CS, RDS, NEC  
8 24.9 28.3 1340 g, male 7/7/7 
placental abruption, CS, RDS, 
NEC, sepsis, neonatal death 
9 30.7 31.7 1160 g, female 8/8/8 placental abruption, CS 
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Table 9. Procedure characteristics of pregnancies with severe oligohydramnios treated with 
transabdominal amnioinfusion. Comparison of cases resulted in delivery and spontaneous abortion.  
Statistical comparisons were performed with the Mann-Whitney U test and the Fisher exact test for 
continuous and categorical variables, respectively. Latency period: interval from first infusion to 
abortion/delivery. GA: gestational age; APTA: antepartum transabdominal amnioinfusion; S.D.: standard 
deviation; n.s.: statistically not significant; OR: odds ratio; 95% CI: 95% confidence interval 
This is basically a consequence of the high proportion of spontaneous abortion in the second 
trimester, which was mainly the result of the procedure-related rupture of the membranes (7 of 16 
second trimester cases). These findings do not correlate with observations in other 
investigations
97,167
. Chhabra et al. conducted a case-control study of 100 pregnant women with 
oligohydramnios
97
. Although the amnioinfusion population included not only patients with severe, 
but also patients with moderate oligohydramnios, decreases in perinatal mortality (4% of study the 
group vs. 18% of the controls), postural deformities (0% in the study group and 4% in the controls) 
and the rate of CS (18% in the cases vs. 46% in the controls) were demonstrated. Gramellini et al.
144
 
achieved a significantly longer latency period in the group of women with oligohydramnios without 
PPROM (30 days vs. 9 days p < 0.05). In our experience, the pregnant women who developed 
spontaneous abortion revealed two very important characteristics: rapidly evolving PPROM and 
retroamniotic filling of the infused fluid. If APTA is followed by PPROM within a short time 
period (3 days) in the second trimester, then the risk of spontaneous abortion is fairly high. A 
possible underlying mechanism of action of the fulminant PPROM could be that the long-acting 
lower intrauterine pressure may lead to a damaged integrity of the amniotic membranes with a 
lower resistance during stretching during the continuously increasing pressure in the course of 
APTA. If rupture does not occur in the first 3 days, then the probability of the prolongation of 
gestation is significantly increased, but more than one procedure is typically required (62.5%) due 
to the recurrence of the oligohydramnios. As a special finding, we observed the retroamniotic filling 
of saline in 4 cases, suggesting the iatrogenic rupture of the membranes at the infusion site as a 
   Pregnancy 
followed by 
delivery (n = 9) 
 Procedure-related 
spontaneous 








OR (95% CI) 







 n.s.  
Latency period (days) 
(mean) 
 
54.4 ± 42.1  
 
4.3 ± 4.4  0.001 
0.44 
(0.21-0.92) 
Single procedure  4 44.4  10 100 n.s.  
Volume infused at first 
APTA (ml) (mean ± S.D.) 




340.0 ± 115.9  n.s.  
Volume infused at all 
APTAs (ml) (mean± S.D.) 
 
444.1 ± 93.6  
 
308.9 ± 101.1  < 0.05  
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major adverse technical complication of APTA. A floating amniotic membrane is visualized 
immediately after the instillation of fluid into the amniotic cavity in these cases. The 20-30 ml 
saline solution coming into contact with the uterine wall behind the amniotic membranes may 
induce uterine irritability and contractions. Retroamniotic filling of infused fluid between the 
amniotic membrane and the uterine wall may also lead to separation of the membrane from the 
uterine wall, resulting in vaginal leakage of the AF shortly after APTA in every case.  
In the vast majority (75%) of the cases, the severe idiopathic oligohydramnios developed in 
the second trimester. Strong et al.
164
 noted a 4-cm AFI increase following an intrauterine infusion of 
250 ml of saline solution. The amount infused on a single occasion of APTA is usually lower than 
that in our study. In Chabbra’s report, an infusion of 250 ml of saline solution caused a mean AFI 




 described a mean increase in the SDP of 1.89 cm following 
a mean infused volume of 283 ml fluid, resulting in a 23.5% pregnancy loss rate. As compared with 
other studies
97,144,164,168
, severe idiopathic oligohydramnios was treated with a significantly higher 
volume of infused fluid in our study (the mean amount of saline infused was 397.3 ml saline) with 
the idea of a not too frequent APTA for those pregnant women who have severe oligohydramnios, 
and the risk of spontaneous abortion or PPROM was higher. However, it is very controversial that a 
higher volume of saline infused into the amniotic cavity poses a lower risk of rupture. In other 
words, a higher initial AFI requires a lower amount of infused saline, which involves a higher 
probability of rupture of the membranes fairly rapidly. Nevertheless, it can be concluded that the 
earlier the severe idiopathic oligohydramnios develops, the higher the risk of rupture of the 
membranes and spontaneous abortion following APTA. 
Although no maternal intraprocedural complications were recorded, the rate of placental 
abruption in our study group is noteworthy. We experienced placental abruption in 3 pregnancies 
(15%) within several days after the last APTA (mean: 12.7 days; range: 7-24 days). This proportion 
is in line with the 9-16.7% rate reported in the literature
114-116
. However, the APTA procedure does 
not seem to increase the risk of this complication, since a similar rate of placental abruption was 
found in the APTA cases to that in the cases without intervention (16.0 vs. 23%)
114
. This is 
supported by the fact that oligohydramnios has been shown to be an independent risk factor for 
placental abruption
169-171
. If we consider the results of previous reports, the benefits of the 
procedure exceed the risk of spontaneous abortion
163
. APTA decreases the rate of pulmonary 
hypoplasia as the most dangerous neonatal consequence of permanent oligohydramnios. In line with 




We conducted a retrospective analysis on the pregnancies complicated with third trimester 
intrauterine fetal death. Despite the outstanding autopsy rate, the proportion of unexplained 
stillbirths remained high. Maternal obesity, lack of adequate antenatal care and maternal 
hypertensive disorders were the most frequent maternal risk factors, while IUGR, oligohydramnios 
and fetal macrosomia were the most important fetal conditions. Our results underline the 
importance of antenatal care and effective screening for intrauterine growth disorders and 
oligohydramnios in the third trimester.  
The proper management of oligohydramnios and PPROM in the second and early third 
trimester is still not sufficiently established. In a meta-analysis, we compared the results of 
conservative management with invasive approaches such as APTA and AP procedures. We 
demonstrated that the invasive approach increases the time until delivery, which is essential in 
improving the perinatal survival. Both invasive methods moderate the consequences of 
oligohydramnios such as pulmonary hypoplasia and postural deformities, while the occurrence of 
maternal complications also decreased. Our results indicate that APTA is a suitable method in the 
management of sPPROM, while AP is appropriate in the treatment of iPPROM.  
We performed an observational study on pregnants treated with APTA because of severe 
idiopathic oligohydramnios (AFI < 5) between 16-34 weeks. In the majority of cases, the 
oligohydramnios developed in the second trimester. PPROM, active labor and  chorioamnionitis 
were excluded. The mean prolongation of the pregnancies was almost 4 weeks, and especially serial 
procedures resulted in a longer latency time. As a new finding, an inverse correlation was found 
between the amount infused and the probability of PPROM. Immediate retroamniotic filling of 
saline solution after the start of the procedure with a floating amniotic membrane predicted 
spontaneous abortion within 48 h. Since procedure-related maternal complications were not 
observed, APTA is a suitable method for reducing oligohydramnios-related neonatal complications 
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Blessed is the one 
    who does not walk in step with the wicked 
or stand in the way that sinners take 
    or sit in the company of mockers, 
 
but whose delight is in the law of the LORD, 
    and who meditates on his law day and night. 
 
That person is like a tree planted by streams of water, 
    which yields its fruit in season 
and whose leaf does not wither— 





A Doktori Értekezés magyar nyelvű összefoglalása 
 
Bevezetés 
A magzatvíz ideális környezetet biztosít a magzati növekedés számára. Védelmet nyújt a 
sérülések ellen, lehetőséget biztosít a magzatmozgásokhoz, amelyek alapvetőek a csont- és 
izomrendszer normál fejlődéséhez. A magzatvíz szerepet játszik a magzati metabolikus 
folyamatokban, meghatározott hőmérsékletet biztosít és esszenciális a tüdő egészséges fejlődése 
szempontjából is. Míg a magzatvíz összetételének szabályozása rendkívül szoros és 
rendellenességei ritkák, addig a magzatvíz mennyiségi eltérései jóval gyakrabban fordulnak elő. A 
magzati kültakaró szarusodását követően a magzatvíz körforgásában szerepet játszó tényezők jól 
meghatározottak és állatkísérletes adatok alapján javarészt ismertek.  
A terhességek 4-4,9%-a jár kórosan csökkent magzatvíz mennyiséggel. 
Oligohydramnionnak definiáljuk a terhességi kornak megfelelő magzatvíz volumen 5 percentilis, 
vagy az alatti mennyiségét. A súlyos mértékű csökkenés alapvetően 6 fő okra vezethető vissza: 1) 
magzati fejlődési rendellenesség; 2) idő előtti burokrepedés; 3) izolált/idiopathiás forma; 4) lepényi 
elégtelenség; 5) többes terhességekben jelentkező szövődmény; 6) iatrogen. Az oligohydramnion 
leggyakrabban a 13-21 és a 34-42 terhességi hetek között jelentkezik. A klinikai gyakorlatban a 
magzatvíz mennyiségének becslése ultrahangvizsgálattal történik, a szubjektív megítélésen túl két 
számítási módszert használnak elterjedten: 1) magzatvíz-index, mely során a méh négy 
quadransában a magzatvíz-zsebek vertikális méretét összegzik; 2) legnagyobb magzatvíz-zseb: a 
legnagyobb magzatvíz-zseb vertikális átmérőjét mérik. 
A harmadik trimeszterben jelentkező oligohydramnion esetén emelkedett a nem 
megnyugtató kardiotokográfiás regisztrátumok és a szülésindukciók gyakorisága. Ugyanígy 
gyakrabban fordul elő meconium aspiráció, az újszülött intenzív osztályon való ápolása, illetve 
emelkedett a perinatalis halálozás. Mindezek ellenére nem egyértelmű az összefüggés az alacsony 
köldökzsinórvér pH és a csökkent magzatvíz mennyiség között. Egyes vizsgálatok eredménye 
szerint az oligohydramnion csak a magzat méhen belüli növekedési retardációjával együtt 
jelentkezve jelent additív kockázatot, míg az izolált oligohydramnion nem emeli a perinatalis 
morbiditást. 
A 24-26. terhességi hét előtt kialakult oligohydramnion jelentős kockázati tényező az 
újszülött pulmonalis hypoplasiája és a váz-izomrendszeri deformitások szempontjából. A 
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pulmonalis hypoplasia mortalitása eléri a 80%-ot. Mivel a megfelelő mennyiségű magzatvíz 
elengedhetetlen a tüdő egészséges fejlődéséhez, így feltételezhető, hogy a magzatvíz 
mennyiségének helyreállítása jótékony hatású a tüdőfejlődés szempontjából. A második 
trimeszterben és a korai harmadik trimeszterben jelentkező oligohydramnion sok esetben idő előtti 
burokrepedés kapcsán alakul ki, amely tovább rontja a prognózist. 
Munkám fókuszában az oligohydramnion jelentőségének felmérése, illetve kezelésének 
lehetőségei álltak. Kutatásunk három fő részre osztható: 
1. Harmadik trimeszter során intrauterin magzati elhalással szövődött terhességekben 
vizsgáltuk retrospektíven az oligohydramnion előfordulását, az anyai és magzati rizikófaktorok 
gyakoriságát, a magzat elhalásának okát, illetve megvizsgáltuk ezek kapcsolatát. 
2. Az oligohydramnion kezelésére a nemzetközi gyakorlatban három eljárás elfogadott, 
úgymint konzervatív kezelés, transabdominalis amnioinfuzió és az amniopatch technika. Meta-
analízist végeztünk és összehasonlítottuk a 13-26. terhességi hét között jelentkező oligohydramnion 
esetén ezeknek a kezelési módszereknek az eredményességét, különös tekintettel a perinatalis 
halálozás, a pulmonalis hypoplasia, valamint a végtagdeformitások előfordulására. 
3. Saját beteganyagunkban megvizsgáltuk a transabdominalis amnioinfúzió eredményességét 
16-34. gestatiós hét között jelentkező idiopathiás oligohydramnionnal szövődött terhességek esetén.    
 
Az oligohydramnion és más rizikófaktorok vizsgálata harmadik trimeszteri 
intrauterin magzati elhalással szövődött terhességekben a foetopathologiai és lepény 
szövettani eredmények alapján 
 
Anyag és módszer 
1996-2010 között a Szegedi Tudományegyetem Szülészeti-Nőgyógyászati Klinikán lezajlott 
harmadik trimeszteri halvaszülések adatai kerültek retrospektív módon feldolgozásra. Vizsgáltuk az 
ismert rizikófaktorok előfordulását, valamint a magzat és a méhlepény szövettani eredményei 
alapján az elhalás lehetséges okát. A magzati elhalás okának meghatározásában a klinikai tényezők 
is figyelembe lettek véve. 
 
Eredmények 
A vizsgált 15 éves periódus alatt 29897 szülésből 140 halvaszülés történt (4,7‰), 126 
esetben (90%) egyes terhességben, míg 14 esetben (10%) ikerterhességben. Az átlagos terhességi 





) (22,1%), a gondozatlan terhesség (20,7%), illetve a hypertoniával járó kórképek (19,3%) 
adódtak. Az adatokat az 1. táblázat (Table 1. – 13. oldal) szemlélteti. A magzat növekedési 
retardációja (47,8%), az oligohydramnion (10%), illetve az excesszív magzati növekedés (8,6%) 
voltak a leggyakoribb magzati rizikófaktorok. Az eredményeket a 2. táblázat (Table 2. – 13. oldal) 
mutatja be. Az ismeretlen eredetű magzati veszteség magas aránya (42,1%) mellett a leggyakoribb 
haláloknak a lepényi elégtelenség (27,1%) és a köldökzsinór eredetű magzati elhalás (15,0%) 
bizonyult. Intrapartum magzati elhalás nem történt. Az adatok a 3. táblázatban (Table 3. - 14. oldal), 
illetve az 1. ábrán (Figure 1. – 15. oldal) láthatóak. Vizsgálatunkban az oligohydramnion és a 
magzat növekedési retardációjának előfordulása szignifikáns összefüggést mutatott. Az 




A harmadik trimeszterben bekövetkező magzati elhalás incidenciája fontos jellemzője a 
szülészeti tevékenységnek, mindemellett a perinatalis mortalitásban jelentős szereppel bír. 
Vizsgálatunkban az előfordulási gyakorisága 4,7‰–nek adódott, amely megfelel a fejlett 
országokban tapasztaltaknak. A kiemelkedő szövettani vizsgálati arány (97,9%) ellenére a magzati 
elhalás aetiologiája jelentős hányadban (42,1%) ismeretlen maradt. Hasonlóképpen, más 
tanulmányokban az ismeretlen magzati veszteség előfordulása 23,2-66,2% között változik, de az oki 
csoportok felosztása nagymértékben függ az értékelés során alkalmazott klasszifikáció típusától.  
Vizsgálati anyagunkban az oligohydramnion előfordulási gyakorisága duplája (10%) volt, 
mint amit populációs megfigyelések kapcsán közöltek. Az esetek közel négyötöde a magzat 
növekedési elmaradásával társult. A magzatvíz csökkent mennyiségének prediktív szerepe a 
magzati elhalás tekintetében továbbra sem egyértelmű. Chamberlain és munkatársai kutatásuk során 
a perinatalis mortalitás ötvenötszörös emelkedését figyelték meg oligohydramnion esetén. Chhabra 
és munkatársai anyagában a magas rizikójú terhességek 18%-a perinatalis veszteséggel végződött, 
amennyiben oligohydramnion volt jelen. A szakirodalmi adatok ismeretében a mi megfigyelésünk 
is alátámasztani látszik azt a véleményt, miszerint az oligohydramnion a magzati veszteség 







A második és korai harmadik (13-26 hét) trimeszterben jelentkező oligohydramnion 
kezelési lehetőségei 
 
Anyag és módszer 
A szakirodalom meta-analízisét végeztük annak meghatározására, hogy a jelenleg elfogadott 
három módszer (konzervatív kezelés, transabdominalis amnioinfúzió, amniopatch technika) közül 
melytől várható a legjobb eredmény a 13-26. terhességi hét között fellépő oligohydramnion 
kezelésében. A konzervatív kezelés és a transabdominalis amnioinfúziós csoportban a témával 
foglalkozó 2000 és 2013 között megjelent tanulmányokat, míg az amniopatch csoportban az összes 
eddig megjelent tanulmányt tekintettük át. Vizsgáltuk a terhesség prolongációjának idejét (latencia 
idő: kezelés kezdete és terhesség befejeződése közt eltelt idő), a perinatalis halálozást/túlélést, a 
pulmonalis hypoplasia, végtagi deformitások előfordulását, valamint a súlyos anyai szövődmények 
(sepsis, korai lepényleválás) gyakoriságát. Analízisünk során χ2-, és Student t-tesztet alkalmaztunk, 
statisztikailag szignifikánsnak a p ≤ 0,05 eredményt tekintettük. 
 
Eredmények 
A konzervatív kezelés csoportjában hét, a transabdominalis amnioinfúzió csoportjában 
kilenc, az amniopatch csoportban 12 tanulmányt analizáltunk. Az áttekintett publikációkat 
összefoglalva prezentálja a 4., 5. és 6. táblázat (Table 4. – 20. oldal, Table 5. - 21. oldal, Table 6. – 
22 és 23. oldal). A konzervatív kezelés a terhességeket átlagosan 11,8 nappal prolongálta, ugyanez 
az időtartam 37,4 nap (p < 0,001) transabdominalis amnioinfúzió és 44 nap (p < 0,001) amniopatch 
technika alkalmazása kapcsán. A neonatalis túlélés 29,3%, 49,1%, 61,4% (p < 0.05) volt a 
konzervatív, amnioinfúziós és amniopatch technikával kezelt csoportokban. Az aktívan kezelt 
csoportokban a terhességek ideje szignifikánsan hosszabb volt a konzervatívan kezelt csoporthoz 
képest. Szintén jelentős csökkenés volt megfigyelhető a pulmonalis hypoplasia és a végtagi 
deformitások előfordulási gyakorisága, illetve az anyai komplikációk gyakorisága között. Az 
eredményeket a 2. ábra (Figure 2. – 24. oldal) prezentálja. 
 
Megbeszélés 
 Vizsgálatunkban igyekeztünk a legfrissebb eredmények analízisére törekedni, mivel a neonatalis 
intenzív terápiás eszköztár rohamos fejlődése jelentősen befolyásolja a perinatalis mortalitási és 
morbiditása mutatókat. Ugyanakkor a 13-26. terhességi hét között jelentkező oligohydramnion 
prognózisa továbbra sem megnyugtató. A magzati fejlődési rendellenességhez társuló eseteket nem 
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számítva, ebben a terhességi korban az oligohydramnion egyik leggyakoribb oka az idő előtti 
burokrepedés. A konzervatív megközelítés alapja az antibiotikum és tocolyticus kezelés a terhesség 
prolongálása érdekében, majd kortikoszteroidok alkalmazása a tüdő érésének gyorsítására. 
Ugyanakkor vizsgálatunk alapján konzervatív kezeléssel ebben a gestatiós korban szerény 
eredmények érhetőek el, a terhességek 73%-a magzatburok megrepedését követő 2 héten belül 
befejeződik. Ez a latencia idő rendszerint nem elegendő a magzat életben maradási esélyeinek 
növeléséhez. 
 A transabdominalis amnioinfúzió során a beavatkozás célja a magzatvíz mennyiségének 
helyreállítása, ezáltal a terhesség prolongálása és az oligohydramnionhoz kötődő magzati 
szövődmények elhárítása. Amniocentesishez használt tűvel a legnagyobb magzatvíz-zsebet 
megszúrva izotóniás oldat (0,9% NaCl oldat, vagy Ringer-Lactat oldat) juttatható a méh űrébe. 
Analízisünk alapján a perinatalis túlélést az eljárás szignifikánsan növeli. Ez az eredmény egyrészt a 
hosszabb latencia idővel, másrészt a pulmonalis hypoplasia előfordulásának csökkenésével 
magyarázható. A prognózis szempontjából az amnioinfúziót követő magzatvízvesztés mértéke 
kulcsfontosságú. Amennyiben az oligohydramnion 48 órán belül visszatér és sorozatos 
amnioinfúziók szükségesek, rosszabb neonatalis túlélés és a tüdőhypoplasia gyakoribb előfordulása 
várható. Ugyanakkor intakt magzatburok mellett jelentkező oligohydramnion esetén a sorozatban 
végzett amnioinfúziós kezelés a neonatalis kimenetel javulásával jár. 
 Az elmúlt időszakban a terhesség alatti invazív diagnosztika mellett az intrauterin sebészeti 
eljárások is elérhető lehetőséggé váltak a szülészeti gyakorlatban. A beavatkozások egyik 
leggyakoribb szövődménye az iatrogen burokrepedés, amely 1,7-30% gyakorisággal fordul elő a 
beavatkozás típusától függően. Az ilyen jellegű burokrepedések kezelésére fejlesztették ki az 
amniopatch technikát, mely során megfelelő arányban izotóniás sóoldatot, thrombocyta 
szuszpenziót és alvadási faktorokat tartalmazó cryoprecipitátumot juttatnak az amnionűrbe. A 
bejuttatott összetevők következtében a burokrepedés helyén fehér színű coagulum képződik, amely 
a magzatburok sérülését elzárja. Tanulmányunk alapján a legmagasabb túlélési arányt ez a módszer 
adja, míg a pulmonalis hypoplasia és a végtagdeformitások aránya 1% alatt marad. Fontos, hogy a 
módszer alapvetően csak iatrogen burokrepedés eseteiben alkalmazható, spontán burokrepedések 
esetében a szabálytalan amnionrés és a társuló fertőzések miatt a módszer javarészt eredménytelen. 
 Analízisünk alapján elmondható, hogy a 13-26. terhességi hét között jelentkező 
oligohydramnion kezelésében a vizsgált aktív módszerek eredményessége felülmúlja a konzervatív 
megközelítés eredményeit. Spontán burokrepedés, illetve intakt magzatburok mellett jelentkező 
oligohydramnion esetében transabdominalis amniocentesis, míg iatrogen burokrepedés esetében 




Súlyos fokú idiopathiás oligohydramnion kezelése transabdominalis amnioinfúzióval 
 
Anyag és módszer 
Munkánk során 2009 és 2012 között a Szegedi Tudományegyetem Szülészeti-
Nőgyógyászati Klinika Ultrahang Laboratóriumában transabdominalis amnioinfúzióval kezelt 
terhességek kimenetelét vizsgáltuk. A transabdominalis amnioinfúzió feltételei a következők voltak: 
1) súlyos oligohydramnion (magzatvíz index <5); 2) 16-34. terhességi hét; 3) singularis terhesség; 
4) negatív hüvelyváladék prolactin teszt; 5) a beteg teljeskörű felvilágosítást követően elnyert 
beleegyezése. Kizárási kritériumok voltak: 1) idő előtti burokrepedés; 2) aktív vetélés vagy szülés 
egyéb tünetei; 3) anyai vagy magzati fertőzés jelei; 4) lepényleválás ultrahang vagy klinikai jelei; 5) 
diagnosztizált, az élettel összeegyeztethetetlen magzati fejlődési rendellenesség; 6) amennyiben a 
gravida a beavatkozásba nem egyezett bele, illetve beleegyezését visszavonta. Az amnioinfúziót 
transabdominalisan, ultrahang ellenőrzés mellett végeztük 0,9% NaCl oldat bejuttatásával. A 
beavatkozást a normál magzatvízmennyiség eléréséig folytattuk. Ezt követően, a korábban 
esetlegesen nem diagnosztizált fejlődési rendellenességek felismerése érdekében ismételt részletes 
ultrahangvizsgálat történt. A magzatvíz mennyiségét a beavatkozást követően másnap, majd hetente 
ellenőriztük. Amennyiben a magzatvíz index újra 5 alá csökkent, a beavatkozást megismételtük. 
Statisztikai számításokra Kruskal-Wallis tesztet, Mann-Whitney U tesztet, χ2 próbát és Fisher exact 
tesztet használtunk, szignifikánsnak a p ≤ 0,05 eredményt tekintettük. 
 
Eredmények 
A beválogatási kritériumoknak összesen 20 terhes felelt meg. Az első amnioinfúzió 
időpontjában az átlagos terhességi kor 22,6 hét (16-33,9) volt. Amnioinfúzió egy alkalommal 
történt 14 terhességben, két alkalommal 3 terhességben, három alkalommal 2 terhességben és négy 
alkalommal 1 terhességben. A beavatkozások 70%-a a második trimeszterben történt. Tíz esetben 
(50%) az amnioinfúziót spontán vetélés követte. Ezek közül négy terhességben a beavatkozás 
kezdetén a retroamnialis tér telődését figyeltük meg, a spontán vetélés mind a négy esetben 48 órán 
belül megindult. A retroamnialis telődést a 4. ábra (Figure 4. – 33. oldal) mutatja be. Egy 
terhességben már a harmadik trimeszterben a magzat méhen belüli elhalása igazolódott. Kilenc 
graviditás végződött élveszüléssel. A latencia idő átlagosan 27,6 ± 37,2 napnak bizonyult. A 
beavatkozások időrendjét és kimenetelét sematikusan a 3. ábra (Figure 3. – 31. oldal) mutatja be. A 
sorozatos amnioinfúzióban részesült terhességek esetén a latencia szignifikánsan hosszabb volt az 
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egyszeri beavatkozásban részesülők eredményénél (69 nap versus 10 nap, p = 0,002). A vetéléssel 
és a szüléssel végződő esetek összehasonlítása látható a 7. és a 9. táblázatban (Table 7. – 32. oldal, 
Table 9. – 35. oldal) (a méhen belüli elhalással végződő esetet a statisztikai analízisből kizártuk). A 
szüléssel végződött esetek jellemzői kiemelve a 8. táblázatban (Table 8. – 34. oldal) láthatóak.  
 
Megbeszélés 
Vizsgálatunkban a második trimeszteri vetéléseknek köszönhetően a magzati veszteség a 
várakozást felülmúlta (55%). Ez az eredmény eltér a szakirodalomban közölt adatoktól, ahol a 
perinatalis halálozás csökkenését írták le amnioinfúzióval kezelt terhességekben. Tapasztalataink 
szerint amennyiben a beavatkozást követően 3 napon belül spontán burokrepedés következik be, 
vagy az amnioinfúzió során retroamnialis telődés látható, a vetélés kockázata rendkívül magas. 
Minél korábban alakul ki a súlyos oligohydramnion, a burokrepedés és a spontán vetélés esélye 
annál magasabb. Terheseink döntő többségében (75%) a magzatvíz mennyiségének csökkenése a 
második trimeszter folyamán jelentkezett. Amennyiben 3 napon belül nem történik burokrepedés, a 
terhesség prolongálásának esélye szignifikánsan emelkedik, de az esetek nagy részében (62,5%) 
több alkalommal végzett amnioinfúzió válik szükségessé. Új megfigyelésként inverz összefüggést 
találtunk az amnioinfúzió volumene és a spontán burokrepedés esélye között. A beavatkozások 
során anyai szövődmény nem fordult elő. Ugyanakkor vizsgált terheseink között a korai 
lepényleválás jelentős gyakoriságot (15%) ért el. Más tanulmányok hasonló eredményt közölnek, de 
úgy tűnik, hogy a korai lepényleválásért nem az amnioinfúzió, hanem maga az oligohydramnion a 
felelős. 
 Az irodalmi adatokat is figyelembe véve az antepartum amnioinfúzió lehetséges megoldás az 
idiopathiás oligohydramnion kezelésében, de ennek ellenére a magzatvíz mennyiségének második 
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